Virax Biolabs Group Ltd (NASDAQ:VRAX) does about 4.31M shares in volume on a normal day but saw 7562517 shares change hands in the recent trading day. The company now has a market cap of 12.86M USD. Its current market price is $5.45, marking an increase of 5.21% compared to the previous close of $5.18. The 52 week high reached by this stock is $9.00 whilst the lowest price level in 52 weeks is $0.60.
Virax Biolabs Group Ltd (VRAX) has a 20-day trading average at $2.26 and the current price is -39.44% off the 52-week high compared with 808.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.67 and its 200-day simple moving average is $1.30. If we look at the stock’s price movements over the week, volatility stands at 56.97%, which decreases to 32.59% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 67.83 to suggest the stock is neutral.
The consensus objective for the share price is $20.00, suggesting that the stock has a potential upside of 72.75% over the period.
The current price level is 165.69%, 241.33%, and 324.05% away from its SMA20, SMA50, and SMA200 respectively, with the VRAX price moving below the 50-day SMA on current market day. Virax Biolabs Group Ltd (VRAX) stock is up 155.87% over the week and 365.81% over the past month. Its price is 273.29% year-to-date and 47.30% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 72.75 percent from here.
Outstanding shares total 2.57M with insiders holding 26.80% of the shares and institutional holders owning 3.02% of the company’s common stock. The company has a return on investment of -121.48% and return on equity of -92.92%. The beta has a value of 2.01. Price to book ratio is 2.61 and price to sales ratio is 80.39.
